Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AN2 Therapeutics, Inc. (Nasdaq: ANTX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. AN2 describes itself as a clinical-stage biopharmaceutical company developing novel small molecule therapeutics from its boron chemistry platform, with programs in Chagas disease, melioidosis, NTM lung disease caused by Mycobacterium abscessus, and oncology targets.
Periodic and current reports such as Forms 10-K, 10-Q, and 8-K provide detail on AN2’s research and development expenses, cash position, and progress across its pipeline. For example, recent Form 8-K filings reference press releases reporting quarterly financial results, including operating expenses and net loss, and describe how the company is advancing clinical trials and collaborations. These documents help investors understand how AN2 funds and prioritizes its infectious disease and oncology programs.
Regulatory filings can also disclose capital structure changes. A Form 8-K describes AN2’s issuance of pre-funded warrants in exchange for common stock to an institutional investor, including key terms such as exercise price and beneficial ownership limitations. Such filings give insight into how the company structures financing while managing ownership thresholds.
On this page, users can access AN2’s annual reports (Form 10-K) and quarterly reports (Form 10-Q) once filed, along with current reports (Form 8-K) that cover material events, collaborations, and financial updates. AI-powered summaries on Stock Titan are designed to highlight the main points in lengthy filings, helping readers quickly identify items related to clinical development, cash runway, or capital transactions without reading every line.
Investors interested in AN2’s ongoing work in Chagas disease, melioidosis, NTM lung disease, tuberculosis collaborations, and oncology targets can use the filings page to review the company’s official disclosures and track how its boron chemistry platform is reflected in its regulatory reporting.
AN2 Therapeutics director Aziz Kabeer received a grant of 20,400 stock options (right to buy) on February 20, 2026. The options have an exercise price of $0.00 per share and are held directly.
The option shares are scheduled to vest on February 20, 2027, provided Kabeer continues to provide service to the company through that date. After this grant, he holds 20,400 derivative securities related to the company’s stock options.
AN2 Therapeutics director Margaret M. FitzPatrick received a grant of stock options for 20,400 shares of AN2 Therapeutics, Inc. common stock. The options carry an exercise price of $0.00 per share and are reported as a direct derivative holding.
The option shares are scheduled to vest on February 20, 2027, provided FitzPatrick continues to provide service to the company through that date. After this award, she holds a total of 20,400 stock options according to the filing.
Zakrzewski Joseph S reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Joseph S. Zakrzewski reported receiving a grant of stock options for 20,400 shares on February 20, 2026. These options were awarded at no purchase price on the grant date and represent his total reported derivative holdings of 20,400 options after the transaction.
According to the disclosure, the option shares will vest on February 20, 2027, provided he continues to provide service to the company through that date. This filing reflects an equity-based compensation award rather than an open‑market purchase or sale.
Almitas Capital LLC reported a new significant ownership position in AN2 Therapeutics, Inc. The firm disclosed beneficial ownership of 2,975,164 shares of common stock and warrants, representing about 5.39% of the class. Almitas holds sole voting and dispositive power over all reported securities.
The filing states these securities were acquired and are held in the ordinary course of business and are not intended to change or influence control of AN2 Therapeutics. The position crosses the 5% threshold that requires public disclosure under Schedule 13G rules.
AN2 Therapeutics, Inc. shareholder Eric Easom reports beneficial ownership of 2,232,004 shares of common stock, representing 7.9% of the class. This percentage is based on 27,402,024 shares outstanding as of November 3, 2025, as disclosed in the company’s Quarterly Report on Form 10-Q.
The position includes 36,880 shares held directly, 1,259,882 shares held by various family trusts where Easom serves as trustee, 61,063 restricted stock units scheduled to vest within 60 days of December 31, 2025, and 874,179 stock options that are vested or will vest within the same 60-day period. Easom reports sole voting and dispositive power over all 2,232,004 shares and no shared voting or dispositive authority.
AN2 Therapeutics’ Principal Accounting Officer, Sarah Joanne Williams, filed an initial statement of beneficial ownership as of January 26, 2026. She directly holds 18,800 shares of common stock, which include remaining restricted stock units (RSUs) that vest over four-year schedules beginning May 28, 2024 and January 1, 2025.
Williams also holds stock options to purchase 21,875 shares at $1.13 per share, expiring on February 25, 2035, and options for 23,700 shares at $2.07 per share, expiring on June 16, 2034. These options vest gradually over four years, subject to her continued service with the company.
AN2 Therapeutics, Inc. reports leadership and compensation changes in its finance organization. The Board appointed Sarah Williams as Vice President, Controller and Principal Accounting Officer, effective February 1, 2026, succeeding Lucy Day in the principal accounting role while Ms. Day remains Chief Financial Officer and Principal Financial Officer.
Williams, a CPA with prior roles at Gritstone Bio, Bio-Rad, BDO USA and Crowe Horwath, will receive an annual base salary of $310,000 and a target bonus equal to 30% of base salary, and will participate in the company’s standard indemnity and severance arrangements. Under an amended employment agreement reflecting cost-savings efforts, Ms. Day’s annual base salary is set at $335,400 through March 2026 and will decrease to $223,600 beginning April 1, 2026, with eligibility for 50% of severance benefits under the Officer Severance Plan if involuntarily terminated not in connection with a change in control. Her outstanding equity awards continue to vest while she provides services.
AN2 Therapeutics director Kabeer Aziz received 11,560 shares of common stock on January 12, 2026 as equity compensation. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and all of them vest immediately. Following this grant, Aziz directly holds 52,479 shares of AN2 Therapeutics common stock.
In addition, entities associated with Aziz hold significant indirect positions. Adjuvant Global Health Technology Fund, L.P. holds 1,995,958 shares and Adjuvant Global Health Technology Fund DE, L.P. holds 377,542 shares, with their general partners and management entities involved in voting and dispositive power. Each person and entity, including Aziz, disclaims beneficial ownership of these indirectly held shares except to the extent of any pecuniary interest.
AN2 Therapeutics director Patricia A. Martin received 3,650 shares of common stock on 01/12/2026 as equity compensation. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and all of them vest immediately, meaning there is no waiting period before they belong to her. Following this grant, Martin beneficially owns 16,905 shares of AN2 Therapeutics common stock, held directly.
AN2 Therapeutics director Gilbert Lynn Marks reported a stock-based compensation grant of 11,560 shares of common stock on January 12, 2026. The shares were issued at a price of $0.00 per share under the company’s non-employee director compensation policy, in lieu of cash fees. According to the disclosure, all of these shares vest immediately.
Following this transaction, Marks directly beneficially owns 75,309 shares of AN2 Therapeutics common stock. The filing characterizes this as a routine equity grant for board service rather than an open-market purchase or sale.